Routine 10b5-1 plan sale by a director with no material signal. Monitor for future insider filings to detect any sustained selling pattern.
RYTM drugs
RYTM drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 23 $106.19entry
- T+1 · 5mo ago +1.28%α +1.33% · $107.55
- T+5 · 5mo ago +3.63%α +2.61% · $110.04
- T+20 · 4mo ago −1.50%α −2.66% · $104.60
- T+60 · 2mo ago −7.70%α −10.95% · $98.01
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Director Lynn Tetrault filed a Form 144 to sell 37,000 shares via option exercise, valued at approximately $3.58 million, under a 10b5-1 plan adopted on 12/15/2025. The sale is small relative to the company's $6.6B market cap and represents routine insider diversification with no material read-through for the stock.
Key Facts
- Director Lynn Tetrault intends to sell 37,000 shares of common stock.
- Estimated proceeds of $3,581,230 (based on filing price).
- Sale is pursuant to a 10b5-1 plan adopted on 12/15/2025.
- Sale date is 06/22/2026, same day as filing.
- Sale represents approximately 0.05% of RYTM's $6.6B market cap.
Financial Impact
Director sale of ~$3.58M; 0.05% of market cap.
Risk Factors
- Minimal, no material risk to stock from this filing alone.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001950047-26-006392 |
| Document: 0001950047-26-006392-index.html | 0001950047-26-006392 |
| Document: 0001950047-26-006392.txt | 0001950047-26-006392 |
Track record
26 reports on RYTM
9 of 14 bullish or bearish reports moved the stock their way by T+5. Best: +32.06% at T+60 after the May 1, 2026 report. 11 of 14 went positive at some point.
Filters
- Nov 16, 2026today Press Release Bullish 5/10 Entry $107.48 Now $107.48 +0.00% settles Nov 24
- Nov 4, 202612d ago Institutional Cluster Neutral 3/10 Entry $110.68 to $112.16 Now $107.48 −2.89% ▲ +1.34% +2.25% vs SPY
- Nov 4, 202612d ago Press Release Bullish 5/10 Entry $110.68 to $112.16 Now $107.48 −2.89% ▲ +1.34% +2.25% vs SPY
- Nov 3, 202613d ago 8-K Bullish 6/10 No price data
- Nov 3, 202613d ago Press Release Bullish 6/10 Entry $86.44 to $113.95 Now $107.48 +24.34% ▲ +31.83% +32.41% vs SPY
- Nov 2, 202614d ago Press Release Neutral 5/10 Entry $86.44 to $113.95 Now $107.48 +24.34% ▲ +31.83% +32.41% vs SPY
- Oct 13, 20264w ago Press Release Bullish 6/10 Entry $86.71 to $88.62 Now $107.48 +23.95% ▲ +2.20% +1.75% vs SPY
- Oct 13, 20264w ago SC 13G Neutral 3/10 Entry $86.61 to $90.20 Now $107.48 +24.10% ▲ +4.14% +5.30% vs SPY
- Sep 14, 20269w ago 144 Bearish 5/10 Entry $96.77 to $99.27 Now $107.48 −11.07% ▼ −2.58% −0.47% vs SPY
- Aug 17, 202613w ago Insider Cluster Bearish 6/10 Entry $115.25 to $113.35 Now $107.48 +6.74% ▲ +1.65% +1.45% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers